Methods: The current study describes a comparative performance assessment between Luminex MAGPIX® and FLEXMAP 3D® platforms to detect miR-122 in human serum. Experiments were performed under comparable conditions using DESTINA’s ChemiRNATM technology on the two Luminex platforms. Assay procedure: a) Modified capture probes (complementary to target miR-122) are conjugated onto Luminex microspheres; b) Microspheres are incubated with serum sample; c) Modified capture probes hybridize with miR-122, forming a chemical pocket; d) A modified base binds in the pocket which can be detected after the application of streptavidin-phycoerythrin. This comparative study has included six serum samples of liver-diseased individuals, as well as four control samples of symptom-free individuals, measured in triplicates and quantified using a 9-point standard curve.
Results: We observed FLEXMAP to be more sensitive in detecting miRNA-122 and resulting in higher signal intensities than MAGPIX. This result was not unexpected as MAGPIX measures fluorescence with CCD cameras after LED illumination of a single layer of microspheres, whereas FLEXMAP uses a flow cytometer-based technology in combination with lasers.
Conclusions: ChemiRNA™ Technology applied to Luminex microspheres enables direct quantification of miR-122 and can be used in combination with both platforms (MAGPIX and FLEXMAP) depending on given sensitivity requirements.
|Publikationsstatus||Veröffentlicht - 8 Nov. 2023|
|Veranstaltung||xMAP® Connect EMEA 2023: xMAP Connect event - Amsterdam, Amsterdam, Niederlande|
Dauer: 8 Nov. 2023 → 9 Nov. 2023
|Sonstiges||xMAP® Connect EMEA 2023|
|Zeitraum||8/11/23 → 9/11/23|
- Molecular Diagnostics